- Home
- MIST vs IPHA Comparison
MIST vs IPHA Comparison
Compare MIST & IPHA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | MIST | IPHA |
|---|---|---|
| Founded | 2003 | 1999 |
| Country | Canada | France |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 176.3M | 169.6M |
| IPO Year | N/A | 2019 |
Fundamental Metrics
Financial Performance| Metric | MIST | IPHA |
|---|---|---|
| Price | $1.95 | $1.75 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 4 | 3 |
| Target Price | ★ $8.50 | $5.00 |
| AVG Volume (30 Days) | ★ 3.4M | 21.6K |
| Earning Date | 03-12-2026 | 09-17-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | ★ $14,839,695.00 |
| Revenue This Year | N/A | $22.29 |
| Revenue Next Year | N/A | $43.90 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $0.63 | $1.63 |
| 52 Week High | $3.06 | $2.63 |
Technical Indicators
Market Signals| Indicator | MIST | IPHA |
|---|---|---|
| Relative Strength Index (RSI) | 41.12 | 51.09 |
| Support Level | $1.97 | $1.74 |
| Resistance Level | $2.06 | $1.85 |
| Average True Range (ATR) | 0.12 | 0.08 |
| MACD | 0.00 | 0.01 |
| Stochastic Oscillator | 18.75 | 62.50 |
Price Performance
Historical ComparisonAbout MIST Milestone Pharmaceuticals Inc.
Milestone Pharmaceuticals Inc is a biopharmaceutical company dedicated to developing and commercializing etripamil for the treatment of cardiovascular medicines. Etripamil is a calcium channel blocker developed as a rapid-onset nasal spray to be administered by the patient to treat episodes of paroxysmal supraventricular tachycardia, or PSVT. The company has an ongoing Phase 2 clinical trial for patients with atrial fibrillation experiencing a rapid ventricular rate (AFib-RVR).
About IPHA Innate Pharma S.A. ADS
Innate Pharma SA is a clinical-stage biotechnology company. It is engaged in developing immunotherapies for cancer patients. Its approach is to harness the innate immune system through therapeutic antibodies and its ANKET (Antibody-based NK cell Engager Therapeutics) proprietary platform. The company's revenue results from payments received to research, collaboration, and licensing agreements signed with pharmaceutical companies. Its product pipeline includes lacutamab, monalizumab, IPH5201, IPH5301, IPH6101, IPH62, IPH6401 and IPH6501.